Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Change in Inventory (2018 - 2025)

Ultragenyx Pharmaceutical (RARE) has disclosed Change in Inventory for 8 consecutive years, with -$150000.0 as the latest value for Q4 2025.

  • Quarterly Change in Inventory fell 106.67% to -$150000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $6.0 million through Dec 2025, down 45.45% year-over-year, with the annual reading at $6.0 million for FY2025, 45.45% down from the prior year.
  • Change in Inventory for Q4 2025 was -$150000.0 at Ultragenyx Pharmaceutical, down from $5.6 million in the prior quarter.
  • The five-year high for Change in Inventory was $5.6 million in Q3 2025, with the low at -$474000.0 in Q1 2021.
  • Average Change in Inventory over 5 years is $1.8 million, with a median of $1.8 million recorded in 2023.
  • The sharpest move saw Change in Inventory tumbled 218.12% in 2021, then surged 1782.98% in 2022.
  • Over 5 years, Change in Inventory stood at $990000.0 in 2021, then surged by 324.75% to $4.2 million in 2022, then tumbled by 51.82% to $2.0 million in 2023, then increased by 11.01% to $2.2 million in 2024, then tumbled by 106.67% to -$150000.0 in 2025.
  • According to Business Quant data, Change in Inventory over the past three periods came in at -$150000.0, $5.6 million, and -$208000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.